Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With Men (APACHES)
Primary Purpose
Hiv Infection
Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Standard proctologic examination
High resolution anoscopy
Biopsy(ies) during High Resolution Anoscopy
High Resolution Anoscopy biannually
Sponsored by
About this trial
This is an interventional diagnostic trial for Hiv Infection
Eligibility Criteria
Inclusion Criteria:
- Men who have sex with men
- At least 35 years old
- HIV-positive (documented search of HIV infection, with HIV status determined according to HAS algorithm)
- Signed informed consent
- Affiliated to or beneficiary of French social security
- All severity criteria and evolution of HIV disease are accepted (including AIDS stage and co-infections)
Exclusion Criteria:
- Contraindication to biopsy
- History of anal cancer or pelvic radiotherapy
- AIN2/3 treated during previous year
- Current anticancer chemotherapy or within 24 months before inclusion
- Difficulty in evaluation (anus reshaped and/or scarred)
- Individual placed under judicial protection
- Foreseen absence which may hamper participation; insufficient motivation; associated pathology with priority for care
Sites / Locations
- Diaconesses
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Subjects
Arm Description
Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
Outcomes
Primary Outcome Measures
Evaluation of high-grade anal lesions by high resolution anoscopy
Evaluation of anal HPV infection by DNA, RNA and protein detection
Quantification of spontaneous regression of high-grade anal lesions
Secondary Outcome Measures
Evaluation of anal HPV infection by DNA, RNA and protein detection
Evaluation of anal HPV infection by DNA, RNA and protein detection
Evaluation of anal HPV infection by DNA, RNA and protein detection
Evaluation of anal HPV infection by DNA, RNA and protein detection
Full Information
NCT ID
NCT02287961
First Posted
October 15, 2014
Last Updated
December 4, 2020
Sponsor
ANRS, Emerging Infectious Diseases
1. Study Identification
Unique Protocol Identification Number
NCT02287961
Brief Title
Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With Men
Acronym
APACHES
Official Title
Natural History of Anal Human Papillomavirus Infection and Associated Disease in HIV-infected Men Who Have Sex With Men: Towards an Evidence Base for the Prevention of Anal Cancer.
Study Type
Interventional
2. Study Status
Record Verification Date
December 2020
Overall Recruitment Status
Unknown status
Study Start Date
December 2014 (Actual)
Primary Completion Date
June 2021 (Anticipated)
Study Completion Date
June 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ANRS, Emerging Infectious Diseases
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Multicentric epidemiological non-comparative study in France characterising evolution of anal Human papillomavirus (HPV) infection and related lesions and evaluating markers associated with the observed evolution.
Estimated enrolment: 500
Principal Outcomes
Detection of high-grade cytological and histological anal lesions by high resolution anoscopy
Spontaneous regression of high-grade anal lesions
Detection of anal HPV infection
Intervention (procedure):
Patient medical interview (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
Standard proctologic examination with digital rectal examination and 2 anal swabs (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
High resolution anoscopy (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
Only if lesion suggestive of Anal Intraepithelial Neoplasia (AIN) detected during High Resolution Anoscopy (HRA):
- anal biopsy(ies) during HRA
Only if high-grade lesion:
- HRA biannually
Detailed Description
Intervention (procedure):
Patient medical interview (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
Standard proctologic examination with digital rectal examination and 2 anal swabs (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
High resolution anoscopy (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
Only if lesion suggestive of Anal Intraepithelial Neoplasia (AIN) detected during High Resolution Anoscopy (HRA):
- anal biopsy(ies) during HRA
Only if high-grade lesion (Atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H), High grade Superficial Intra-epithelial Lesion (HSIL) or AIN2/3):
- HRA biannually
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hiv Infection
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
500 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Subjects
Arm Type
Other
Arm Description
Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy
High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
Intervention Type
Procedure
Intervention Name(s)
Standard proctologic examination
Intervention Description
(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
Intervention Type
Procedure
Intervention Name(s)
High resolution anoscopy
Intervention Description
at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
Intervention Type
Procedure
Intervention Name(s)
Biopsy(ies) during High Resolution Anoscopy
Intervention Description
only if lesion suggestive of AIN detected during High Resolution Anoscopy
Intervention Type
Procedure
Intervention Name(s)
High Resolution Anoscopy biannually
Intervention Description
Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
Primary Outcome Measure Information:
Title
Evaluation of high-grade anal lesions by high resolution anoscopy
Time Frame
Initial inclusion visit
Title
Evaluation of anal HPV infection by DNA, RNA and protein detection
Time Frame
Initial inclusion visit
Title
Quantification of spontaneous regression of high-grade anal lesions
Time Frame
Month 24
Secondary Outcome Measure Information:
Title
Evaluation of anal HPV infection by DNA, RNA and protein detection
Time Frame
Month 6
Title
Evaluation of anal HPV infection by DNA, RNA and protein detection
Time Frame
Month 12
Title
Evaluation of anal HPV infection by DNA, RNA and protein detection
Time Frame
Month 18
Title
Evaluation of anal HPV infection by DNA, RNA and protein detection
Time Frame
Month 24
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men who have sex with men
At least 35 years old
HIV-positive (documented search of HIV infection, with HIV status determined according to HAS algorithm)
Signed informed consent
Affiliated to or beneficiary of French social security
All severity criteria and evolution of HIV disease are accepted (including AIDS stage and co-infections)
Exclusion Criteria:
Contraindication to biopsy
History of anal cancer or pelvic radiotherapy
AIN2/3 treated during previous year
Current anticancer chemotherapy or within 24 months before inclusion
Difficulty in evaluation (anus reshaped and/or scarred)
Individual placed under judicial protection
Foreseen absence which may hamper participation; insufficient motivation; associated pathology with priority for care
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Isabelle Etienney
Organizational Affiliation
Hôpital Diaconesses Paris
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gary Clifford
Organizational Affiliation
International Agency for Research on Cancer
Official's Role
Study Director
Facility Information:
Facility Name
Diaconesses
City
Paris
Country
France
12. IPD Sharing Statement
Links:
URL
http://anrs.fr
Description
Agence nationale de recherches sur le sida et les hépatites virales (ANRS)
Learn more about this trial
Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With Men
We'll reach out to this number within 24 hrs